An open, randomized-controlled, multi-center phase-II clinical trial of individualized immunosuppression with intravenously administered donor modified immune cells (MIC) compared to standard-of-care in living donor kidney transplantation
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Mitomycin C induced peripheral blood mononuclear cells TolerogenixX (Primary)
- Indications Transplant rejection
- Focus Therapeutic Use
- Sponsors TolerogenixX
Most Recent Events
- 26 Dec 2022 New trial record